The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Wed., Aug. 31, 11:58 AM

Slide #10. Recro Pharma, Inc. Secondary Offering

Company: Recro Pharma, Inc. (NASDAQ:REPH)
Date announced: 8/15/2016
Shares Offered: 1,986,666
Date of Pricing: 8/16/2016
Price Per Share: $7.50
Secondary Offering Details: Recro Pharma, Inc. ("Recro" or the "Company") (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings, currently developing non-opioid products for the treatment of serious acute pain, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Recro. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 8/16- Recro Pharma, Inc. ("Recro" or the "Company") (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings, currently developing non-opioid products for the treatment of serious acute pain, today announced the pricing of an underwritten public offering of 1,986,666 shares of its common stock at a price of $7.50 per share.

Recro Pharma is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery. Co.'s lead product, an intranasal formulation of Dexmedetomidine (Dex), for pain relief in chronic lower back pain patients. Co.'s product also include:Dex-IN, for the treatment of post-operative pain and for the treatment of cancer breakthrough pain, the next anticipated program after acute pain following surgery; Dex-SL, a product candidate for the treatment of chronic pain; and Fadolmidine, a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain.
Open the REPH Page at The Online Investor »

Company Name:  Recro Pharma, Inc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding REPH:  2
Total Market Value Held by ETFs:  $139950
Total Market Capitalization:  $93.00M
% of Market Cap. Held by ETFs:  0.15%
 

Open the REPH Page at The Online Investor (in a new window) »

August 31, 2016    11:58 AM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.